Daniel Fero
InvestorManaging Director at OMX Ventures · Investment Manager at Nina Capital
Boston, Massachusetts
Writes $500K – $15M checks · typically $7.8M
Find your path to Daniel
34 people in our graph share verified history with Daniel — schools, employers, funds. One of them is your warm intro.
About
Dan Fero is a co-founder and managing partner at OMX Ventures, focusing on platform companies that use a data-driven approach to product discovery and development, and supporting founders turning scientific discoveries into products. He previously was a venture investor at Merieux Equity Partners and a strategy consultant at L.E.K. Consulting in Boston, and co-founded the precision oncology company Uereka Biosciences. He holds a PhD in Biomedical Sciences from UCSD and a BA in biology from Rhode Island College.
Contact· self-published, not guessed
Invests in
BiotechDeep TechHealthtech
Investments
Investor
CellsonicsMatterworksMythic TherapeuticsReAx BiotechnologiesType6 Therapeutics
Per the firm's website.
Colleagues at OMX Ventures
Network3
Investors connected to Daniel in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Daniel Fero?
- Dan Fero is a co-founder and managing partner at OMX Ventures, focusing on platform companies that use a data-driven approach to product discovery and development, and supporting founders turning scientific discoveries into products. He previously was a venture investor at Merieux Equity Partners and a strategy consultant at L.E.K. Consulting in Boston, and co-founded the precision oncology company Uereka Biosciences. He holds a PhD in Biomedical Sciences from UCSD and a BA in biology from Rhode Island College.
- Where does Daniel Fero work?
- Daniel Fero is Managing Director at OMX Ventures.
- What does Daniel Fero invest in?
- Daniel Fero invests in Biotech, Deep Tech, Healthtech.
- What check size does Daniel Fero write?
- Daniel Fero typically writes checks of $500K – $15M.
- What companies has Daniel Fero invested in?
- Investments tracked here include Cellsonics, Matterworks, Mythic Therapeutics, ReAx Biotechnologies, Type6 Therapeutics.








